{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T02:54:46Z","timestamp":1768704886260,"version":"3.49.0"},"reference-count":122,"publisher":"Informa UK Limited","issue":"4","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2024,3,3]]},"DOI":"10.1080\/14656566.2024.2332610","type":"journal-article","created":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T07:15:55Z","timestamp":1711350955000},"page":"395-408","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":12,"title":["Promising therapies for the treatment of myasthenia gravis"],"prefix":"10.1080","volume":"25","author":[{"given":"Sanem Pinar","family":"Uysal","sequence":"first","affiliation":[{"name":"Department of Neurology, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9738-9547","authenticated-orcid":false,"given":"John A.","family":"Morren","sequence":"additional","affiliation":[{"name":"Neuromuscular Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2024,3,25]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70063-8"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2014.01.003"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.13560"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756285615605700"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/14728214.2021.1952982"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11216394"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2013.12.011"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2012.06840.x"},{"issue":"1","key":"e_1_3_5_11_1","first-page":"82","article-title":"Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3","volume":"67","author":"R\u00f8dgaard A","year":"1987","unstructured":"R\u00f8dgaard A, Nielsen FC, Djurup R, et al. Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3. Clin Exp Immunol. 1987;67(1):82\u20138.","journal-title":"Clin Exp Immunol"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/85520"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1586\/eci.12.34"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00212"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011124"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-023-00825-y"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/CND.0000000000000377"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncpneuro0810"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-008-3002-0"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.19.2367"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.662856"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/ncn3.12301"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.13522"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2019.105630"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1515\/revneuro-2014-0021"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.4161\/viru.26515"},{"key":"e_1_3_5_27_1","unstructured":"Study details | a study to examine the efficacy and safety of Pozelimab and cemdisiran combination therapy in adult patients with symptomatic generalized myasthenia gravis | ClinicalTrials.Gov [accessed 2023 Dec 20]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05070858"},{"key":"e_1_3_5_28_1","unstructured":"Prevail study | see if you may qualify | generalized myasthenia gravis study [accessed 2023 Dec 20]. Available from: https:\/\/prevailmgstudy.alexionclinicaltrials.com\/"},{"key":"e_1_3_5_29_1","unstructured":"Study details | study of ALXN2050 in adult participants with generalized myasthenia gravis | ClinicalTrials.Gov [accessed 2023 Dec 20]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05218096"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2019.4694"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23839"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30369-1"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjmed-2022-000241"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.556104"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2014.11.003"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-09-876136"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/evidoa2100066"},{"key":"e_1_3_5_38_1","unstructured":"Ultomiris approved in the US for adults with generalised myasthenia gravis [accessed 2023 Dec 20]. Available from: https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2022\/ultomiris-approved-in-the-us-for-adults-with-generalised-myasthenia-gravis.html"},{"key":"e_1_3_5_39_1","unstructured":"Zilucoplan | C172H278N24O55 | CID 133083018 - PubChem [accessed 2023 Dec 20]. Available from: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/133083018"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2021.1897567"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.5125"},{"key":"e_1_3_5_42_1","unstructured":"Ra Pharmaceuticals Receives Orphan Drug Designation from the U.S. FDA for zilucoplan for the treatment of myasthenia gravis | business wire [accessed 2024 Jan 9]. Available from: https:\/\/www.businesswire.com\/news\/home\/20190904005284\/en\/Ra-Pharmaceuticals-Receives-Orphan-Drug-Designation-from-the-U.S.-FDA-for-Zilucoplan-for-the-Treatment-of-Myasthenia-Gravis"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00080-7"},{"key":"e_1_3_5_44_1","unstructured":"UCB announces U.S. FDA approval of ZILBRYSQ[\u00ae] (zilucoplan) for the treatment of adults with generalized myasthenia gravis | UCB [accessed 2023 Dec 20]. Available from: https:\/\/www.ucb.com\/stories-media\/Press-Releases\/article\/UCB-announces-US-FDA-approval-of-ZILBRYSQR-zilucoplan-for-the-treatment-of-adults-with-generalized-myasthenia-gravis"},{"key":"e_1_3_5_45_1","unstructured":"Study details | open-label extension of Zilucoplan in subjects with generalized myasthenia gravis | ClinicalTrials.Gov [accessed 2023 Dec 20]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04225871"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00821-1"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.03052"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.07.016"},{"key":"e_1_3_5_49_1","unstructured":"A study of nipocalimab administered to adults with generalized myasthenia gravis - full text view - ClinicalTrials.Gov [accessed 2023 Dec 20]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04951622"},{"key":"e_1_3_5_50_1","unstructured":"Study details | phase 3 study to assess the efficacy and safety of Batoclimab as induction and maintenance therapy in adult participants with generalized myasthenia gravis | ClinicalTrials.Gov [accessed 2023 Dec 20]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05403541"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2022.2136167"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2022-0298"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007600"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI97911"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00159-9"},{"key":"e_1_3_5_56_1","unstructured":"ADAPT\/ADAPT+ study show improvements in myasthenia gravis efficacy scales with efgartigimod [accessed 2023 Dec 20]. Available from: https:\/\/www.neurologylive.com\/view\/adapt-study-show-improvements-myasthenia-gravis-efficacy-scales-efgartigimod"},{"key":"e_1_3_5_57_1","unstructured":"Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia Gravis - Full Text View - ClinicalTrials.gov [accessed 2023 Dec 20]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04735432"},{"key":"e_1_3_5_58_1","unstructured":"Subcutaneous Efgartigimod PH20 Demonstrates Efficacy for Generalized Myasthenia Gravis in Open Label ADAPT-SC+ Trial [accessed 2023 Dec 20]. Available from: https:\/\/www.neurologylive.com\/view\/subcutaneous-efgartigimod-ph20-demonstrates-efficacy-generalized-mg-open-label-adapt-sc-trial"},{"key":"e_1_3_5_59_1","unstructured":"argenx Announces Positive Topline Phase 3 Data From ADAPT-SC Study Evaluating Subcutaneous Efgartigimod for Generalized Myasthenia Gravis | Business Wire [accessed 2023 Dec 20]. Available from: https:\/\/www.businesswire.com\/news\/home\/20220321005941\/en\/argenx-Announces-Positive-Topline-Phase-3-Data-From-ADAPT-SC-Study-Evaluating-Subcutaneous-Efgartigimod-for-Generalized-Myasthenia-Gravis"},{"key":"e_1_3_5_60_1","unstructured":"Efgartigimod Approved for Generalized Myasthenia Gravis [accessed 2023 Dec 20]. Available from: https:\/\/www.neurologylive.com\/view\/efgartigimod-approved-for-generalized-myasthenia-gravis"},{"key":"e_1_3_5_61_1","unstructured":"FDA approves subcutaneous efgartigimod as treatment for generalized myasthenia gravis [accessed 2023 Dec 20]. Available from: https:\/\/www.neurologylive.com\/view\/fda-approves-subcutaneous-efgartigimod-vyvgart-hytrulo-generalized-myasthenia-gravis"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011108"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00077-7"},{"key":"e_1_3_5_64_1","unstructured":"Janssen to highlight latest research from Nipocalimab Clinical Development Program to address unmet need in myasthenia gravis at AANEM 2023 meeting [accessed 2023 Dec 20]. Available from: https:\/\/www.jnj.com\/janssen-to-highlight-latest-research-from-nipocalimab-clinical-development-program-to-address-unmet-need-in-myasthenia-gravis-at-aanem-2023-meeting"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-022-00345-9"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25973"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00622"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-020-00092-2"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1053\/J.SEMINHEMATOL.2010.01.011"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25597"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000013121"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.2887"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.13535"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004341"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000000453"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000734"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00167-8"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13317-017-0100-y"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-020-00443-w"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.1002\/MUS.26707"},{"key":"e_1_3_5_82_1","unstructured":"Study Details | Myasthenia Gravis Inebilizumab Trial | ClinicalTrials.gov [accessed 2023 Dec 20]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04524273"},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.63.6.851"},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15266"},{"key":"e_1_3_5_85_1","unstructured":"A study of TAK-079 in people with generalized myasthenia gravis - full text view - ClinicalTrials.Gov [accessed 2023 Dec 20]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04159805"},{"key":"e_1_3_5_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2023.11.013"},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.828191"},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6101(02)00027-8"},{"key":"e_1_3_5_89_1","unstructured":"Study details | efficacy and safety of Tocilizumab in the treatment of generalized myasthenia gravis | ClinicalTrials.Gov [accessed 2023 Dec 20]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05067348"},{"key":"e_1_3_5_90_1","unstructured":"Study details | a study to evaluate efficacy safety pharmacokinetics and pharmacodynamics of satralizumab in patients with generalized myasthenia gravis | ClinicalTrials.Gov [accessed 2023 Dec 20]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04963270"},{"key":"e_1_3_5_91_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109017"},{"key":"e_1_3_5_92_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1314258"},{"key":"e_1_3_5_93_1","unstructured":"Study details | therapy of antibody-mediated autoimmune diseases by Bortezomib (TAVAB) | ClinicalTrials.Gov [accessed 2023 Dec 20]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02102594"},{"key":"e_1_3_5_94_1","doi-asserted-by":"publisher","DOI":"10.1136\/BMJOPEN-2018-024523"},{"key":"e_1_3_5_95_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.2006.2.3.271"},{"key":"e_1_3_5_96_1","doi-asserted-by":"publisher","DOI":"10.1084\/JEM.190.11.1697"},{"key":"e_1_3_5_97_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005323"},{"key":"e_1_3_5_98_1","unstructured":"Study details | a study of TACI\uff08Transmembrane activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor\uff09-antibody fusion protein injection (RC18) in subjects with systemic myasthenia gravis | ClinicalTrials.Gov [accessed 2023 Dec 20]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04302103"},{"key":"e_1_3_5_99_1","doi-asserted-by":"publisher","DOI":"10.1111\/J.1600-065X.2008.00741.X"},{"key":"e_1_3_5_100_1","unstructured":"Study details | efficacy and safety of tolebrutinib (SAR442168) tablets in adult participants with generalized myasthenia gravis | ClinicalTrials.Gov [accessed 2024 Jan 9]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05132569"},{"key":"e_1_3_5_101_1","doi-asserted-by":"publisher","DOI":"10.2174\/1389201019666180418095526"},{"key":"e_1_3_5_102_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00754-1"},{"key":"e_1_3_5_103_1","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/5727516"},{"key":"e_1_3_5_104_1","doi-asserted-by":"publisher","DOI":"10.1038\/MTO.2016.11"},{"key":"e_1_3_5_105_1","doi-asserted-by":"publisher","DOI":"10.1186\/S40364-017-0102-Y"},{"key":"e_1_3_5_106_1","doi-asserted-by":"publisher","DOI":"10.1038\/S41587-022-01637-Z"},{"key":"e_1_3_5_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00194-1"},{"key":"e_1_3_5_108_1","unstructured":"Study details | open-label study to evaluate the safety of various dosing regimens of MuSK-CAART for MuSK myasthenia gravis | ClinicalTrials.Gov [accessed 2023 Dec 20]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT05451212"},{"key":"e_1_3_5_109_1","doi-asserted-by":"publisher","DOI":"10.1038\/S41591-019-0737-3"},{"key":"e_1_3_5_110_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000531"},{"key":"e_1_3_5_111_1","doi-asserted-by":"publisher","DOI":"10.1101\/CSHPERSPECT.A029082"},{"key":"e_1_3_5_112_1","doi-asserted-by":"publisher","DOI":"10.1001\/JAMANEUROL.2016.0113"},{"key":"e_1_3_5_113_1","unstructured":"Study Details | Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases | ClinicalTrials.gov [accessed 2023 Dec 20]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT00716066"},{"key":"e_1_3_5_114_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.ARCMED.2020.08.006"},{"key":"e_1_3_5_115_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S25716"},{"key":"e_1_3_5_116_1","doi-asserted-by":"publisher","DOI":"10.1385\/JMN:14:1-2:093"},{"key":"e_1_3_5_117_1","doi-asserted-by":"publisher","DOI":"10.1196\/ANNALS.1405.022"},{"key":"e_1_3_5_118_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00538"},{"key":"e_1_3_5_119_1","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0159993"},{"key":"e_1_3_5_120_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004365"},{"key":"e_1_3_5_121_1","doi-asserted-by":"publisher","DOI":"10.4049\/JIMMUNOL.175.3.2018"},{"key":"e_1_3_5_122_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.JAUT.2005.01.013"},{"key":"e_1_3_5_123_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000992"},{"key":"e_1_3_5_124_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S8915"},{"key":"e_1_3_5_125_1","unstructured":"Study details | safety and efficacy of tofacitinib in patients with refractory myasthenia gravis: a pilot study | ClinicalTrials.Gov. [accessed 2023 Dec 20]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04431895"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2024.2332610","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T16:26:19Z","timestamp":1727195179000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2024.2332610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,3]]},"references-count":122,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,3,3]]}},"alternative-id":["10.1080\/14656566.2024.2332610"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2024.2332610","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-01-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}